
Applying AI to adverse event case processing: sharpening the impact of pharmacovigilance
For major pharma brands, for which pharmacovigilance (PV) has up to now primarily involved

For major pharma brands, for which pharmacovigilance (PV) has up to now primarily involved

What was the opportunity? Claudia Lehman, Boehringer Ingelheim (CL): We had already seen considerable